Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study - Takeaways - MDSpire

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study

  • By

  • Wenfang Jin

  • Ying Zhao

  • Yanling Lv

  • Yu Yao

  • Xin Su

  • June 8, 2026

  • 0 min

Share

  • 1

    The study assessed whether the baseline CD4/CD8 lymphocyte ratio predicts early immune-related adverse events in lung cancer patients.

  • 2

    Among 202 patients, 25% developed grade ≥2 immune-related adverse events within 30 days of initiating PD-1/PD-L1 blockade.

  • 3

    A baseline CD4/CD8 ratio <1.65 was found in 63% of patients with early irAEs, compared to 36% of controls, indicating a significant association.

  • 4

    The adjusted odds ratio for a CD4/CD8 ratio <1.65 predicting early irAEs was 3.03, with hypertension and diabetes also contributing modestly.

  • 5

    The final predictive model achieved an area under the curve of 0.78, suggesting reasonable performance in identifying high-risk patients.

Original Source(s)

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study

  • by Wenfang Jin, Ying Zhao, Yanling Lv, Yu Yao, Xin Su

  • June 8, 2026

Related Content

Training on PD-L1 scoring in non-small cell lung cancer with high intra- and inter-reader agreement: results of a worldwide microscopic/digital image-based training of 751 pathologists

Monomorphic epitheliotropic intestinal T-cell lymphoma presenting as acute small intestinal perforation: a case report and exploratory BCL-2–targeted therapy

Feasibility of weekly patient-reported symptom monitoring using patients' own smartphones in outpatient cancer chemotherapy: the SMART-PRO study